Pharmaceutical manufacturing workshop discussion.
Pharmaceutical manufacturing workshop discussion.

The International Pharmaceutical Excipients’ Council (IPEC) India held its Master Class Series 2026-27 on oral solid dosage forms at the SciTech Center in Mumbai. The event gathered formulators, excipient suppliers, technical specialists and regulators to discuss formulation and manufacturing problems linked to conventional, co-processed and novel excipients.

Organisers framed the programme around three goals: pinpoint process-related risks, assess their impact on finished tablets, and share practical ways to resolve manufacturing difficulties. Speakers emphasized a scientific approach to excipient selection, processing and scale-up.

Excipient variability threatens tablet consistency

Co-processed excipients combine two or more materials to improve flow, compressibility, binding and disintegration. While they can simplify formulations, inconsistencies in their manufacture and handling create hurdles for formulators.

Moisture variation in raw materials and composite excipients influences particle strength, powder flow and product stability. Even small changes can shift compressibility and affect tablet weight uniformity.

Variations in particle size distribution during co-processing or milling can affect blend uniformity, tablet compatibility, die filling and tablet weight consistency.

Segregation during material handling, transportation or blending occurs when particles differ in size or density. This separation leads to uneven content distribution and unpredictable performance in the final dosage form.

Excessive heat during drying, granulation or hot-melt extrusion can alter the physical form and functional properties of co-processed excipients. Temperature control is therefore essential to preserve intended functionality.

Changes in excipient suppliers, manufacturing sources or material grades require appropriate requalification. Even if the chemical identity remains the same, variations in raw-material attributes can affect downstream performance, demanding risk assessment and comparative material characterisation.

The pattern mirrors earlier transitions when the industry shifted from single-component binders to multi-component blends, a move that also exposed hidden variability and forced tighter material controls.

Regulatory initiatives and industry response

The U.S. Food and Drug Administration’s PRIME program offers a pathway for independent pre-market safety evaluation of novel excipients, separate from active-ingredient applications. The initiative aims to reduce regulatory uncertainty and encourage innovation.

The United States Pharmacopoeia has launched a Novel Excipients Knowledge Hub and updated General Chapter 1074 to provide scientific data and tiered toxicological assessment methods, supporting developers worldwide.

Read Also: Pharmaceutical Waste Crisis Threatens Environment, Public Health

Standardised testing approaches across the United States, European Union and Asian markets could narrow technical expectation gaps and facilitate acceptance of new excipients.

The masterclass was led by Dr Ajit Singh, chairman of IPEC India, with Dr Ravleen Singh Khurana as managing director of Nitika Pharmaceuticals and honorary secretary of IPEC India. An address by Dr Santosh Indraksha, deputy drugs controller, CDSCO West Zone, and a presentation by Fred Rowley of Solid Dosage Training Inc. USA added regulatory and practical perspectives.

Handling novel excipients

Irregular particle morphology and high cohesiveness characterize many new excipients. These traits promote hopper bridging and powder segregation during high-speed filling, which can disrupt die-fill consistency and lead to tablet-weight variation.

Issues such as capping and lamination emerge when viscoelastic excipients store elastic energy during compression. Upon ejection, rapid energy release may separate the tablet crown or create internal layers, reducing yield and compromising tablet integrity.

Thermal sensitivity presents another obstacle. Certain polymeric matrices possess low melting points or glass-transition temperatures. Exposure to wet-granulation heat or fluid-bed drying can cause particles to agglomerate, fouling equipment and altering intended drug-release profiles.

Because many novel materials lack extensive batch-to-batch performance histories, manufacturers must generate detailed physical specifications before scale-up. Characterisation of flow, compressibility and electrostatic behavior helps anticipate segregation or bridging risks.

Strategic approaches for scale-up

Strategic supplier qualification now extends beyond price comparison. Manufacturers evaluate raw-material attributes, manufacturing processes and historical performance data to ensure consistent functionality across production runs.

Effective risk assessment integrates comparative material studies with process validation. Demonstrating that a new excipient batch behaves equivalently to legacy material reduces the need for full requalification, accelerating formulation timelines.

During the panel discussion, participants highlighted the importance of matching excipient critical attributes to equipment capabilities. Selecting materials compatible with existing granulation and compression technology minimizes retrofitting costs and preserves process robustness.

Case studies presented detailed troubleshooting steps for bilayer tablet compression. Adjustments to punch geometry and dwell time mitigated layer separation, illustrating how targeted process tweaks can resolve complex manufacturing challenges.

Initiatives to Standardize Excipient Safety Assessments

Efforts are underway to provide developers with scientific data, peer-reviewed knowledge, and tiered toxicological evaluation methods for excipient safety assessments. These initiatives aim to establish standardized testing approaches across major pharmaceutical markets, including the U.S., European Union, and Asia. By reducing differences in technical expectations, they support the development and acceptance of innovative excipients. Consistent quality, effective process controls, and harmonized safety evaluations are emphasized to ensure formulation innovations translate into reliable manufacturing performance and finished medicines.